Incyte (INCY) Receives a Hold from Wells Fargo
Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The ...
TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)
In a report released yesterday, Marc Frahm from TD Cowen maintained a Buy rating on Incyte (INCY – Research Report), with a price target of ...
Incyte's skin disease drug fails to impress in late-stage studies; shares drop
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
FiercePharma12d
Incyte's mixed Opzelura data in prurigo nodularis add uncertainty to potential approval bid: analysts
As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest data drop in prurigo nodularis carries a mix of both positives and ...
Morningstar29d
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
Incyte is granted exclusive rights for potential clinical development and commercialization of collaboration products. “As a leader in pharmaceutical innovation, Incyte is continually seeking ...
Yahoo Finance5d
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
- Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET WILMINGTON, Del., March 17, 2025--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced positive ...
Yahoo Finance10d
Incyte (INCY) Up 2.6% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Incyte (INCY). Shares have added about 2.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...
Benzinga.com11d
Incyte Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
In the preceding three months, 6 analysts have released ratings for Incyte INCY, presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ...
Benzinga.com11d
1INCY : Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease...
Discover how to track all 535 Congress member stock trades today. On Saturday, Incyte Corporation INCY revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and TRuE ...
Investing8d
Incyte’s SWOT analysis: stock faces patent cliff as dermatology pipeline grows
Moreover, the highly competitive nature of the pharmaceutical industry means that even if Incyte brings new products to market, they may face intense competition that could limit their commercial ...
Business Wire14d
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 13,351 shares of the Company’s common ...